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Inhibitory receptors (iRs) are frequently associated with “T cell exhaustion”. However, the 
expression of iRs is also dependent on T cell differentiation and activation. Therapeutic 
blockade of various iRs, also referred to as “checkpoint blockade”, is showing 
 unprecedented results in the treatment of cancer patients. Consequently, the clinical 
potential in this field is broad, calling for increased research efforts and rapid refinements in 
the understanding of iR function. In this review, we provide an overview on the significance 
of iR expression for the interpretation of T cell functionality. We summarize how iRs have 
been strongly associated with “T cell exhaustion” and illustrate the parallel evidence 
on the importance of T cell differentiation and activation for the expression of iRs. The 
differentiation subsets of CD8 T cells (naïve, effector, and memory cells) show broad and 
inherent differences in iR expression, while activation leads to strong upregulation of iRs. 
Therefore, changes in iR expression during an immune response are often concomitant 
with T cell differentiation and activation. Sustained expression of iRs in chronic infection 
and in the tumor microenvironment likely reflects a specialized T cell differentiation. In 
these situations of prolonged antigen exposure and chronic inflammation, T cells are 
“downtuned” in order to limit tissue damage. Furthermore, we review the novel “check-
point blockade” treatments and the potential of iRs as biomarkers. Finally, we provide 
recommendations for the immune monitoring of patients to interpret iR expression data 
combined with parameters of activation and differentiation of T cells.
Keywords: inhibitory receptors, T cell exhaustion, activation, differentiation, immune monitoring, immunotherapy, 
checkpoint blockade
definition of inhibitory Receptors
Immune cell function is tightly controlled and fine-tuned via co-stimulatory and co-inhibitory 
molecules. Co-stimulatory receptors were originally described to share a common sequence motif 
called immunoreceptor tyrosine-based activation motif (ITAM) consisting of two YxxL sequences 
separated by 7–12 amino acids (1, 2). This motif binds Zap70/Syk protein tyrosine kinases via their src 
homology 2 domain (SH2) (3). A few years later, an inhibitory motif (immunoreceptor tyrosine-based 
inhibitory motif, ITIM) was discovered in the cytoplasmic tail of Fcγ receptor IIB, a single chain 
low-affinity receptor for the Fc portion of IgG (4, 5). This receptor could inhibit immune activatory 
signals by dimerizing with the respective co-activatory receptors on mast cells, T cells, and B cells (6, 
7). Like the ITAM motif, the ITIM motif interacts with SH2 domains (8–11). Thereafter, proteins that 
featured such ITIM motifs and that related to the immune synapse were classified as co-inhibitory 
molecules or (co-)inhibitory receptors (hereafter referred to as iRs).
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The iRs that are nowadays studied in T cells were first described 
in natural killer cells in the early 90s (12, 13) and were defined as 
follows (3, 5, 12, 14, 15): (a) they possess an ITIM that, (b) when 
phosphorylated, (c) can recruit SHP1 and possibly SHP2 (1, 2, 
9), which (d) in turn interfere with activating receptors to inhibit 
downstream activatory pathways (3, 16). At that time, two families 
of iRs were known: the immunoglobulin superfamily (IgSF) and 
the c-type lectin superfamily (17–20).
Two of the probably most well-studied T cell-related iRs are 
programed cell death 1 (PDCD1, also called PD1) and cytotoxic 
T lymphocyte-associated Antigen 4 (CTLA-4). PD1 was originally 
discovered by screening for genes that are involved in classical pro-
gramed cell death in a mouse lymphoid hybridoma and a mouse 
lymphoid/myeloid progenitor cell line (21). The sequence of its 
human counterpart was described shortly after (22). CTLA-4 was 
discovered already in 1987 (23) as an immunoglobulin receptor, 
but its function was only determined in the mid-90s.
Today, the definition of iRs has changed from the above-
mentioned features to a rather functional definition: most surface 
receptors that are classified as iRs contain an ITIM, such as B 
and T lymphocyte associated (BTLA) and PD1. But in addition, 
receptors that lack an ITIM are recognized as iRs, making the first 
characteristic above (a) no obligation. A prominent example is 
CTLA-4, which contains a Tyr–Xaa–Xaa–Met motif that is thought 
to have inhibitory function (12, 24). Also, lymphocyte-activation 
gene 3 (LAG3) does not feature an ITIM (25). It belongs to the 
CD4 family and binds to MHC class II with high affinity (26). The 
most frequent alternative inhibitory motif is the immune receptor 
tyrosine-based switch motif (ITSM), which also interacts with 
SH2-domain containing phosphatases such as SHIPs (27–30). 
ITSMs can be found in the cytoplasmic tail of PD1 and BTLA 
among other iRs (and in addition to ITIMs). A summary of the 
inhibitory sequence motifs on iRs including less frequent motifs 
can be found in the review by Odorizzi and Wherry (31).
The new functional definition describes iRs as co-inhibitory 
molecules that negatively interfere with T cell activation and 
function. iRs can inhibit T cell functions at several levels (31): (i) 
through competition with co-stimulatory receptors for binding 
to shared ligands or interference in the formation of microclus-
ters and lipid rafts (32–34), (ii) by interfering with downstream 
signals from co-activatory and T cell receptors (TCRs), and (iii) 
by upregulating genes that are involved in T cell dysfunction (35). 
Over the past two decades, the IgSF has grown to include far more 
than 10 members divided into 8 receptor subfamilies (31, 36). A 
comprehensive overview of T cell co-stimulatory and co-iRs and 
their molecular mechanisms can be found in a review by Chen 
and Flies (36).
iRs as Hallmarks in “T cell exhaustion”
Inhibitory receptors were set at the forefront of research interest 
with the description of their involvement in the phenomenon of “T 
cell exhaustion”. The phenomenal clinical impact of the therapeutic 
blockade of iRs to restore T cell function in cancer (as outlined in 
the last parts of our review) has greatly contributed to the wide-
spread acknowledgment of the functional importance of iRs. “T 
cell exhaustion” was coined to describe the functional state of CD8 
T cells that persist but show poor effector functions in mice chroni-
cally infected with LCMV Clone 13 (37). The molecular signature 
of exhausted CD8 T cells was later characterized in this prototypic 
mouse model of LCMV infection, comparing the phenotype and 
functionality of CD8 T cells in chronic (Clone 13 strain) versus 
acute (Armstrong strain) infections (38). As opposed to acute 
infection, where effector CD8 T cells give rise to memory cells 
once the pathogen is cleared, persistent antigen stimulation and 
inflammation in the chronic infection setting leads to progressive 
loss of function in CD8 T cells, termed “T cell exhaustion”. At the 
center of the molecular signature of exhausted CD8 T cells was the 
upregulation of iRs, including PD1, CTLA-4, CD160, and LAG3, 
setting iRs as hallmarks of “T cell exhaustion” (38, 39). In the field 
of “T cell exhaustion”, scientific advances were strongly promoted 
by mouse studies using the prototypic LCMV model (acute versus 
chronic infection). By contrast, the profiling of exhausted CD8 T 
cells in cancer was first done in humans, demonstrating that Melan-
A-specific T cells in melanoma patients share many molecular 
features with exhausted T cells in chronic infection (40). Over the 
last decade, several studies have further linked expression of iRs 
(e.g. PD1, CTLA-4, TIM3, LAG3, CD160, BTLA, and 2B4) to the 
phenomenon of “T cell exhaustion” both in mouse models and in 
patients, in chronic infections, including HIV, hepatitis C virus, 
EBV, malaria, as well as autoimmune disorders such as systemic 
lupus erythematosus and in several cancers (41–50). In these 
various pathological scenarios, expression of multiple and differ-
ent combinations of iRs has been associated with the exhausted 
phenotype of CD8 T cells, implying that iRs are not only diverse but 
also co-regulate “CD8 T cell exhaustion” (51, 52). Consequently, 
iRs have been generally referred to as “exhaustion markers” 
(53–55). Importantly, this knowledge on “T cell  exhaustion” and 
the implication of iRs has had full impact on therapeutic strate-
gies, with the breakthrough of monoclonal antibodies that block 
iRs (also referred to as “checkpoint blockade”) to restore T cell 
function and yielding unprecedented clinical improvements on 
overall survival of cancer patients. This therapeutic breakthrough 
of monoclonal antibodies against iRs and “checkpoint blockade” 
is discussed in the final sections of this review.
understanding iR Function: Tribulations 
Through the “T cell exhaustion” Field 
(Authors’ Path, Part i)
In the framework of the characterization of CD8 T cells in cancer, 
we and others discovered that CD8 T cells in metastasis of mela-
noma patients had increased levels of iRs, as compared to CD8 T 
cell counterparts in circulation (40, 44, 48). This increase of iRs at 
the tumor site correlated with the previously observed decreased 
functional properties of CD8 T cells in metastasis, as opposed 
to blood-derived CD8 T cells (40, 56). Therefore, these studies 
demonstrated that “T cell exhaustion” (increased iR levels and 
diminished T cell function) also occurs in the context of chronic 
antigen stimulation and inflammation in the tumor microenviron-
ment (TME) (involving self antigens), similarly to chronic viral 
infections (involving non-self antigens). “T cell exhaustion” at the 
tumor site constitutes thus the third stumbling block, in addition to 
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the poor naïve repertoire of self antigen-specific CD8 T cells (low 
affinity and precursor frequency: first stumbling block) and the 
poor priming capacity against tumors (inefficient tumor antigen 
presentation and co-stimulation by tumors: second stumbling 
block) [reviewed in Ref. (57)].
As mentioned above, multiple studies showed that CD8 T cells 
in chronic antigen stimulation settings (cancer or viral infections) 
display diminished function associated with increased iR levels. 
However, this association (high iR =  low function) was neither 
a direct proof that an iR per se provoked lower functionality nor 
did this association provide mechanistic insights into the function 
of iRs. In fact, there is as yet limited knowledge concerning iR 
function and the signaling of the various iRs: what are the precise 
molecular pathways, the signaling cascades and events downstream 
of the interactions of iRs with their respective iR ligands? Further 
to structural considerations whereby iRs contain inhibitory motifs 
(described above), the evidence on signaling mechanisms is sum-
marized in the reviews by Chen and Flies (36), Baitsch et al. (57), 
and Odorizzi and Wherry (31).
In order to assess directly the impact of iRs on T cell function, 
we setup an in vitro system to study T cells that express iRs and are 
exposed to TCR activation surrounded by iR ligands. To control 
the presence and dose of each iR ligand, and to avoid uncontrolled 
secondary events from the antigen presenting cell (APC), we 
made use of artificial APCs (aAPC), namely, beads that could be 
coated with the desired dose and composition of iR ligands (58). 
These were cell-sized beads (4.5 μm diameter) covered with epoxy 
groups that covalently attach any protein (or protein mix). We 
used anti-CD3 antibody (OKT3 clone) to activate T cells together 
with combinations of recombinant iR ligands, including human 
PD-L1:Fc (PD1 ligand), HLA-DR (LAG3 ligand), and HVEM:Fc 
(ligand of BTLA and CD160). We initially found that beads coated 
with anti-CD3 and any combination of iR ligands barely activated 
CD8 T cell clones or primary CD8 T cells to produce cytokines in a 
4-h assay, as opposed to beads coated with anti-CD3 only, pointing 
toward strong inhibition by the presence of iR ligands. However, we 
performed quality controls of the APC beads and discovered that 
the procedure used to coat the beads (based on standard protocols) 
lead to the out-competition of anti-CD3 from the surface of the 
beads upon co-incubation with iR ligands, leading the artifactual 
“inhibition” of T cell function by iR ligands (in fact, due to less 
anti-CD3 antibody coated on the beads in presence of iR ligands). 
After optimization of aAPC bead preparation to obtain beads with 
equivalent doses of anti-CD3 in absence or presence of iR ligands, 
the repetition of the experiments revealed that the presence of iR 
ligands did not result in reduced CD8 T cell function (in clones 
nor primary cells), neither in 4-h assays of cytokine production 
nor in proliferation assays for up to 4 days. It is possible that the 
functional impact of iRs differs depending on the context, for 
instance, different T cell types may have different susceptibilities 
to iR-mediated inhibition (“exhausted” CD8 T cells from tumor 
metastasis may be more susceptible than primary cells from blood 
of healthy individuals). Several previous studies had investigated 
iR function using aAPC beads prepared with standard procedures 
without explicit quality control on the bead coating; our experi-
ments using quality-controlled aAPC beads showed that the mere 
presence of iR ligands such as PD-L1 did not lead to inhibition of 
T cell activation (58).
Notwithstanding, in addition to the use of beads coated 
with T cell-stimulatory antibodies and iR ligands, several other 
experimental strategies exist to assess iR function. These include 
the use of T cells over-expressing iRs, stimulated with APC over-
expressing respective iR ligands, as well as the T cell functional 
assays in presence of iR-blocking antibodies.
For instance, the mechanism of PD1 action has been addressed 
by various experimental means. Wei et  al. over-expressed high 
or intermediate levels of PD1 in primary human T cells by RNA 
electroporation and stimulated these with aAPC (K562 or T2) 
over-expressing PD-L1: the different T cell functions tested 
(cytokine secretion, Ca2+ flux, proliferation) were differentially 
sensitive to PD1 expression (59). Similarly, using mouse T cells 
over-expressing PD1 and planar bilayers containing stimulatory 
molecules in combination with PD-L1, Yokosuka et al. showed 
that PD1 forms microclusters with the TCR and recruits SHP2 to 
negatively regulate TCR signaling (60). A multitude of studies have 
shown that blockade of PD1 and other iRs leads to improved T cell 
functionality, including cytotoxicity, proliferation, and cytokine 
production [e.g., Ref. (44, 49)]. Interestingly, in the context of the 
LCMV infection model of “T cell exhaustion”, PD1-blockade may 
reverse dysfunction in PD1int- but not in PD1high-expressing T cells 
(61), emphasizing again that the levels of iR (high or intermediate) 
are crucial to determine the impact and strength of its inhibitory 
action (59). In the case of CTLA-4, several mechanisms of action 
have been proposed, including inhibitory events downstream 
CTLA-4 and interference with TCR signaling as well as T cell-
extrinsic mechanisms [reviewed in Ref. (62, 63)]. For example, it is 
known that CTLA-4 is competing with co-stimulatory B7 ligands 
for binding to CD28. Two models have been suggested, the first in 
which CTLA-4 increases the threshold for T cell activation and the 
second in which CTLA-4 attenuates T cell expansion (64). More 
recently, the efficacy of CTLA-4 blockade in anti-tumor therapy 
has been at least partly attributed to another T cell-extrinsic 
mechanism, namely antibody-dependent cell-mediated cytotoxic-
ity (ADCC), whereby regulatory T cells (Tregs) expressing high 
levels of CTLA-4 are tagged by the CTLA-4-blocking antibody for 
ADCC by macrophages and depleted within the TME (65, 66). 
Moreover, an iR might even have opposite functions depending 
on the molecules that participate to the immune synapse, as is the 
case for TIM3, which is inhibitory if it interacts with CEACAM-1 
and activatory in absence of CEACAM-1 (67). This example shows 
that it is crucial to consider the remainder of interacting partners, 
whether co-stimulatory and co-inhibitory, when assessing iR func-
tion and CD8 T cell functionality. It also impacts on the design of 
strategies to block iRs and reverse T cell function, as it might be 
more relevant to interfere with other interacting partners such as 
CEACAM-1 rather than blocking TIM3. Altogether, the precise 
mechanisms whereby each iR works are as yet not fully defined.
Finally, a commonly practiced strategy to address iR function is 
to assess the functionality of T cells that show positive expression 
of iRs and compare them to iR-negative counterparts. Several 
studies have reported that positive expression of iRs (including 
PD1, CTLA-4, TIM3, LAG3, 2B4, CD160, and BTLA) marked 
cells that expressed less cytokines (44, 50, 68–72). It is in this 
comparative exercise that we have found that the consideration 
of T cell differentiation and activation status is crucial, as will be 
explained in full detail in the following section.
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iR expression is driven by T cell 
Activation and differentiation (Authors’ 
Path, Part ii)
Further to the association of iR expression with “T cell exhaustion” 
in pathological settings, important insights on the significance 
of iR expression for the functionality of T cells have been gained 
from the study of iR expression in CD8 T cells from healthy 
individuals.
Analysis of PBMC from healthy individuals shows, first, that 
circulating CD8 T cells express various iRs in steady-state, and 
second, that iR levels clearly vary depending on T cell differentia-
tion (73, 74) (Figure 1). For instance, iRs such as 2B4, KLRG1, and 
CD160 are expressed at higher levels with increased differentia-
tion. By contrast, BTLA is high on naïve cells and decreases with 
differentiation. PD1 is particularly expressed in effector memory 
(EM) cells. TIM3 is present at low levels on naïve T cells. Other 
iRs such as CTLA-4 and LAG3 are not detectable in steady-state 
in circulating CD8 T cells from healthy donors.
BTLA
TIM3
BTLA
PD1
2B4
KLRG1BTLA KLRG1
CD8 T cells in PBMC from healthy individuals:
Naïve CM EM EMRA
CD160
PD1
2B4
KLRG1
2B4
3-day 
activated blast
TIM3
PD1
CTLA-4
LAG3
2B4
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4-1BB, CD69,
CD25 & CD38
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FiguRe 1 | cd8 T cell subsets are inherently different in iR expression 
and effector functions. The various differentiation subsets that are found in 
circulation in healthy donors are depicted with the iRs that they predominantly 
express. The relative levels of each iR are indicated below each subset, in 
parallel to the capacity for cytokine secretion and CD107a translocation. 
The graphs are based on data from a 6-h intracellular cytokine production 
assay using PBMC from healthy donors (75). Also shown is iR expression in 
activated cells (“activated blast”), together with activation markers, based on a 
3-day stimulation assay on CD8 T cells from healthy donors (75). The size of 
the receptor depicted on cells reflects the relative expression of iRs.
Importantly, the functional capacities of CD8 T cells also 
largely vary according to their differentiation stage. For instance, 
upon stimulation with anti-CD3 and anti-CD28, naïve cells do 
not produce cytokines, while EM cells are most effective at 
producing IFNγ and TNFα, central memory (CM) and EM cells 
at producing IL-2, and EM RA+ (EMRA) cells at expressing 
Granzyme B and at degranulating (CD107a translocation) [Ref. 
(75), Figure 1]. The expression of a multitude of other molecules 
and functions involved in cytokine signaling, cytotoxicity, 
migration, proliferation, apoptosis, senescence, and stemness 
are also well known to vary according to T cell differentiation 
(76–78). There are thus inherent differences in functionality as 
well as iR expression among CD8 T cell subsets. Therefore, in the 
Key concePT 1 | inherent differences
CD8 T cell subsets are inherently different in the expression of a wide array of 
molecules and functionalities, including iR expression. iR expression is tightly 
linked to the differentiation status, and this link is present in healthy immune 
homeostasis.
Analysis of total CD8 T cells
separated into iR+ and iR-
for cytokine analysis:
BTLA
Naïve CM EM EMRA
iR +
iR -
BTLA PD1 BTLA
PD1 PD1BTLA
BTLA+ produce less cytokines
(because most BTLA+ are Naïve)
PD1+ produce more cytokines
(because most PD1+ are EM)
Analysis of CD8 T cells rst by gating on each subset, then 
separated into iR+ and iR- for cytokine analysis:
BTLA+ and - cells within each subset are similarly productive
(30%)(10%) (15%)(50%)(90%) (70%) (40%)
(50% of total) (10% of total) (30% of total) (10% of total)
PD1+ and - cells within each subset are similarly productive
FiguRe 2 | discriminating differentiation subsets is the minimal 
analysis to assess the link between iR expression and functionality of 
cd8 T cells. The significance of iR expression on CD8 T cell function can be 
assessed by analyzing cytokine production by iR-positive versus iR-negative 
cells. The relative capacity for cytokine production in the various subsets is 
depicted by the numbers of orange intracellular dots. As an example, the 
expression of two iRs are shown: BTLA and PD1. The percentage below each 
subset name indicates the relative frequency of that subset within total CD8 T 
cells. The percentages next to each receptor indicate the fraction of cells within 
a given subset that express the receptor (the size of the receptor depicted on 
cells also reflects relative expression of iRs). These percentages are estimated 
based on average values in PBMC of healthy donors (75). When iR-positive 
cells are compared to iR-negative cells within the total CD8 T cells (red arrow), 
artifactual conclusions can be driven due to the inherent differences in iR 
expression and effector function of the various subsets. For example, BTLA+ 
cells in total CD8 T may show less cytokine secretion than their BTLA− 
counterparts, but this is due to the enrichment of Naïve cells in BTLA+ cells, 
which do not produce cytokines as compared to the enrichment of 
differentiated cells in BTLA−. With each subset, BTLA+ and BTLA− are 
comparable cytokine producers. Therefore, it is not “cytokine production 
capacity” (=artifactual conclusion) but “differentiation status” what accounts for 
differences in comparing BTLA+ and BTLA− cells. As a minimal requirement, 
analysis of individual subsets is necessary to adequately address the link 
between iR expression and effector function.
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study of iR expression and T cell function, it is crucial to keep in 
consideration that iR expression is tightly linked to the differen-
tiation status, and that this link is already observable in healthy 
individuals, where it is not related to a particular pathological 
state nor “T cell exhaustion” (this is further described below 
in the Section “Physiological Role of iRs to Regulate T Cells in 
Health and Immune Homeostasis”).
In addition to the conventional differentiation subsets Naïve, 
CM, EM, and EMRA, expression of several iRs has also been 
assessed in the more recently described Naïve-like stem cell-like 
memory T cells (SCM) (77, 79). For instance, in the context of 
Yellow Fever vaccination, we recently showed that human SCM 
CD8 T cells express high levels of BTLA, very low levels of 2B4, 
no PD1, and intermediate levels of KLRG1 (79). This iR profile 
would place them in between Naïve and CM cells in the dif-
ferentiation gradient shown in Figure 1, as is the case for several 
other functions that have been addressed by gene expression 
profiling (77, 79).
The importance of considering T cell differentiation is best 
depicted by the exercise where we compared cytokine produc-
tion by iR-positive CD8 T cells versus iR-negative counterparts, 
either considering the total CD8 T cells (all subsets mixed) or 
following the separation of subsets (75) (Figure 2). To this end, 
we used stimulation with anti-CD3 and anti-CD28, importantly 
in absence of added iR ligands, in order to assess the functional-
ity of iR-positive cells and not the impact of stimulating the iR 
per  se. Given that naïve cells do not produce cytokines upon 
anti-CD3 and anti-CD28 stimulation, the analysis of total CD8 
T cells showed highly significant differences between iR- positive 
versus iR-negative cells in the case of iRs that are inherently 
expressed at clearly distinct levels between naïve versus dif-
ferentiated subsets. Yet, these differences were diminished 
or disappeared when cytokine production was analyzed by 
comparing iR-positive versus iR-negative cells within each 
individual differentiation subset (75) (Figure 2). This applies 
to BTLA (high in naïve) as well as 2B4 and KLRG1 (high in 
differentiated cells). Interestingly, in general, iR-positive cells 
were still largely capable to produce cytokines and did not show 
major impairments as compared to iR-negative counterparts, in 
agreement with previous reports analyzing PD1 in CD8 T cells 
from healthy donors (74).
Altogether, this comparative exercise showed that the direct 
link between positive iR expression and lower cytokine produc-
tion is generally absent or weak, or only applies to a limited 
number of iRs in certain CD8 T cell subsets. Moreover, a failure to 
consider the differentiation status can lead to artifactual conclu-
sions on functional differences between iR-positive and -negative 
cells.
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We also compared iR expression and function in CD8 T cells 
from tumor-infiltrated lymph nodes (TILN) in melanoma patients 
with similar results, in agreement with previous studies where 
we showed that PD1+ CD8 T cells from PBMC from melanoma 
patients are not necessarily impaired (80). In the TME (e.g., TILN), 
however, CD8 T cells can express CTLA-4 and high levels of PD1, 
and positive expression may correlate with lower cytokine produc-
tion (69, 75). In our settings, it is technically difficult to compare 
cytokine levels in iR-positive versus negative cells due to the low 
cytokine production of CD8 T cells from TILN, although a trend 
was seen for less cytokines in PD1+, TIM3+, and CTLA-4+ CD8 T 
cells in TILN (75). Therefore, even in the absence of added inhibi-
tory ligands (only stimulation with anti-CD3 and anti-CD28), the 
impact of iR expression may be context-dependent, e.g. showing 
no effect in CD8 T cells in circulation but negative effects in cells 
from the TME.
In addition, stimulation of healthy donor CD8 T cells for several 
days with anti-CD3 and anti-CD28 showed that certain iRs are 
strongly up-regulated, including PD1, CTLA-4, TIM3, and LAG3. 
Furthermore, such iR upregulation positively correlates with the 
expression of several activation markers, including 4-1BB, CD69, 
CD38, and CD25. This indicated that not only differentiation but 
also the activation status can dictate the levels of iR expression in 
CD8 T cells.
Of note, the broad inter-individual variability in T cell subset 
composition, function, and iR expression (75) further aggravates 
the artifacts in analyzing total CD8 T cells instead of individual 
subsets separately. This is also aggravated in the case where differ-
ent samples are compared (e.g., different tissues, infections, time-
points) that inherently display different composition of CD8 T cell 
subsets and where analyses based on comparison of total CD8 T 
cells undermines variability in differentiation or activation status.
significance of iR expression Beyond 
“T cell exhaustion”
Based on the aforementioned analyses of CD8 T cells in healthy 
individuals, it became clear that both T cell differentiation and 
activation were major drivers of iR expression. Consequently, 
iR expression may, in fact, be an indication of ongoing or recent 
activation in CD8 T cells as well effective T cell differentiation, 
in contrast to the association of iR expression with “T cell 
exhaustion”.
Various lines of evidence exist that iRs participate in T cell 
activation and differentiation, in a “tide model” where iRs can be 
up-regulated in order to counterbalance co-stimulatory signals 
following the peak of activation [reviewed in Ref. (36, 81)]. PD1, 
for instance, was described already in 1996 as a protein that was 
up-regulated in T and B lymphocytes upon activation in vitro (well 
before it was linked to “T cell exhaustion”) (82). In fact, in the 
LCMV model of “T cell exhaustion”, iRs are expressed at high 
levels in the effector phase in both settings, whether in the acute 
or chronic infection setting (38). Yet, only in the acute infection, 
the pathogen is cleared leading to contraction of effector cells 
into memory cells, with the consequent down-modulation of 
iRs, as opposed to the chronic infection, where the expression 
of iRs remains elevated. In addition to T cell differentiation, it 
is important to highlight this “effector/acute” component of 
elevated iR expression (Figure 3), which has been neglected in 
the depiction of “T cell exhaustion” models (39) or only recently 
addressed (36, 41).
In the functional characterization of CD8 T cells, iRs have 
been used as surrogate markers for T cell dysfunction, in a 
“guilty by association” reflex where iR expression would mark 
exhausted cells, even referring to iRs as “exhaustion markers” 
(53–55). However, multiple studies have directly or indirectly 
shown that expression of one or the other iR is not always a sign 
of “T cell exhaustion” but is rather associated with markers 
or transcription factors involved in T cell differentiation and 
activation.
For instance, high co-expression of PD1, 2B4, CD160, and 
KLRG1 on HCV-specific CD8 T cells is linked to a CD127 low 
phenotype (i.e., late differentiation) and recurrent antigen trig-
gering (low epitope diversity) (83). PD1, 2B4, and CD160 are also 
co-expressed in Flu-, EBV-, and CMV-specific CD8 T cells, where 
CD160+ but not PD1+ cells are less functional (84). Similarly, 
in HIV infection, CD160 and PD1 double positive cells are a 
dysfunctional subset of CD8 T cells, as opposed to cells positive 
only for PD1 that are rather in an activated state (85). TIM3 
expression is linked to an EM phenotype and stronger effector 
responses in tuberculosis (86). PD1 levels are increased in Acute 
Friend virus infection yet PD1+ cells are cytotoxic and control 
infection (87). PD1 correlates with activation markers 41BB (88) 
in breast cancer and CD38 in HIV (53). In the AT-3 tumor model 
of breast cancer, PD1high TIM3+ CD8 T cells also express 4-1BB, 
as well as granzyme B, Ki67, and IFNγ, and persist following 
radiotherapy (88).
PD1 has also been shown to regulate the development of CM 
cells following acute vaccinia virus infection in mice: in PD1−/− 
mice, primary and secondary responses are enhanced and CD8 
T cells have a phenotype with high CD62L, CD27, CCR7, and 
IL-2, which supports that a skewing toward the CM phenotype 
occurs in absence of PD1 (89). Along the lines of the role of PD1 
in differentiation, PD1high CD8 T cells in chronic LCMV infection 
express high levels of EOMES, in contrast to PD1int that rather 
express high levels of Tbet (90). Interestingly, the transcription 
factor FoxO1 sustains high PD1 expression, promoting survival 
and differentiation of CD8 T cells in chronic LCMV infection (91). 
The increased levels of PD1, CD160, and 2B4 in total CD8 T cells 
during chronic HIV infection are also associated with Tbetdim and 
EOMEShigh expression (92).
Key concePT 3 | sign of “T cell exhaustion”
The phenomenon of “T cell exhaustion” is characterized by T cell dysfunction 
with elevated levels of iRs. However, iR expression on CD8 T cells is not always 
a sign of T cell dysfunction and does not necessarily correspond to reduced 
T cell functions, but may rather mark activated and/or different subsets of 
functional CD8 T cells.
Key concePT 2 | Artifactual conclusions 
A failure to consider differentiation status can lead to conclusions that are 
drawn from wrong argumentation (artifactual) on functional differences 
between iR-positive and -negative cells. This is illustrated in Figure 2.
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FiguRe 3 | Levels of iR may peak at the effector phase, and may 
further modulate differently during acute versus chronic immune 
responses. Naïve cells express mainly BTLA and low levels of TIM3. Effector 
cells express a wider variety of iRs. The levels of certain iRs such as PD1, 
CTLA-4, LAG3, and TIM3 may peak at the effector phase. Thereafter, iR 
expression differs in chronically stimulated cells (“exhausted cells”) where iRs 
are relatively maintained, as opposed to memory cells after clearance of an 
acute infection where iRs are down-modulated.
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Altogether, in the midst of the implication of iR in “T cell 
exhaustion”, there is thus also diverse evidence that iRs primarily 
participate in T cell activation and differentiation.
This has lead to re-evaluations of the significance of iR as 
“exhaustion markers”, for instance, in the context of SIV infection 
[where PD1 expression was associated with a CCR7− CCR5+ 
phenotype rather than dysfunction per se, questioning the value 
of PD1 as a marker of “immune exhaustion” (93)], as well as in 
cancer [where BTLA and PD1 are proposed to mark cells in a 
“heightened state of T cell activation” (94)].
Physiological Role of iRs to Regulate  
T cells in Health and immune Homeostasis
Expression of iRs is physiologically associated with T cell-
regulatory events that are not linked to pathological processes. In 
the context of “healthy” immune homeostasis, iRs co-evolved with 
co-stimulatory molecules to form a multi-component system of 
positive and negative regulatory signals surrounding TCR stimula-
tion, which supports the fine-tuning of T cell activation. Possibly, 
the initial recognition of the target cell via the TCR receptor is 
priming T cells for response and signaling through co-stimulatory 
or co-iRs determines the direction and intensity of the response.
Thus, the expression of co-stimulatory and co-iRs is not mutu-
ally exclusive. In the “tide model” suggested by Zhu et al. (81), 
the rise and fall of waves of co-stimulatory versus co-inhibitory 
signaling tightly regulates and fine tunes the immune response. The 
diversity of co-stimulatory receptors and iRs on T cells allows to 
control the T cell response at every step, from T cell priming, T cell 
expansion, and contraction, to the various functions of memory 
T cells. In addition, different co-signaling receptors are important 
in CD8 versus CD4 T cell subsets.
Pivotal studies in mice have allowed establishing the principles 
of iR function and their importance for the regulation of the 
immune response using transgene and (conditional) knock-out 
technologies, as well as transplantation or cell transfer experiments. 
Most of the basic knowledge about iRs has been generated and 
confirmed with such models. For instance, CTLA-4-deficient mice 
develop lymphoproliferative disease, which leads to tissue damage 
and ultimately to death within the first month of age (95, 96). In 
addition to its important constitutive expression and function in 
Treg cells (97), CTLA-4 is up-regulated following T cell activation 
(98), and is involved in late stages of T cell priming and systemic 
activation of T cell responses [reviewed in Ref. (99)].
Like CTLA-4, PD1 expression is induced on T cells by activa-
tion (82). PD1-deficient mice develop autoimmune diseases, 
such as lupus-like diseases or dilated cardiomyopathy (100, 
101). When infected with chronic pathogens such as LCMV 
strain 13 or with Mycobacterium tuberculosis, PD1-deficient 
mice develop strong immunopathological reactions and suc-
cumb within days or weeks (100, 102). However, in contrast to 
CTLA-4 in priming, the PD1-pathway rather plays an important 
role at the sites of effector T cell activity, by limiting self-tissue 
damage (101, 103, 104). Upon exposure to target antigen, PD1-
deficient T cells show an increased proliferation compared to 
PD1-expressing T cells (104). This suggests that PD1 is playing 
a role at later stages of the immune responses, when T cells are 
already activated.
Key concePT 4 | co-evolved with co-stimulatory receptors
iRs co-evolved with co-stimulatory receptors to allow for the fine-tuning of 
T cell responses – as such, iRs are not only present in “T cell exhaustion” 
but also have a primary role in the regulation of immune homeostasis and 
preservation of healthy tissue from autoimmunity.
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As described in more detail below, “checkpoint blockade” can 
provoke immune-related adverse events (IRAE). CTLA-4 blockade 
for treatment of melanoma patients provoked grade 3 and grade 4 
IRAE including autoimmune damages in colon, liver, and hormo-
nal glands (105). The immunological side effects are reminiscent 
of those in mice that lack Tregs. Indeed, anti-CTLA-4 antibody 
treatment can lead to Treg depletion via antibody-dependent 
cellular cytotoxicity (65, 66).
These evidences taken together, it becomes clear that each 
iR has a specific role at specific events during the tightly con-
trolled immune response of T cells. The plasticity of the immune 
response requires an interplay of co-stimulatory and co-inhibitory 
signals in order be executed in a beneficial manner for its host 
and without causing unwanted damage of healthy tissue. The 
autoimmune disorders in iR knock-out mice and the IRAE in 
“checkpoint blockade”-treated patients show that iRs such as PD1 
and CTLA-4 are fundamental in the maintenance of a healthy 
immune homeostasis.
Breakthrough in immunotherapy: 
“checkpoint Blockade”
During recent years, novel therapies with iR-specific anti-
bodies (referred to as “checkpoint blockade”) have brought 
major breakthroughs for patients with solid cancers, including 
melanoma and carcinomas of various organs. This unprec-
edented success in immunotherapy of cancer is changing 
the therapeutic principles in clinical oncology, based on the 
conceptual proof that the immune system of many patients 
bears the potential to combat malignant disease up to clinically 
significant levels.
The initial report of clinical benefit for melanoma patients 
by targeting CTLA-4 (106) was followed by rapid publications 
confirming and extending these findings through targeting 
CTLA-4 or PD1 pathways. Two phase 1 clinical trials suggested 
even further improvements for melanoma patients, by combi-
nation therapies with PD1 and CTLA-4 blocking monoclonal 
antibodies (107, 108). This particular combination causes more 
frequent autoimmune toxicities than the single agent therapies 
(109). Nevertheless, the increased clinical benefit for patients 
with metastatic disease justifies the further development of 
“checkpoint blockade”. Today, immunotherapy has reached 
a high level of clinical usefulness. Often, clinical responses 
in melanoma patients are durable, and some patients are still 
disease free after many years (110–113). Progress is evident not 
only in melanoma patients but also in patients with lung and 
kidney cancer, and more recently bladder and head and neck 
cancer patients. Currently, there are more than 300 clinical trials 
registered (www.clinicaltrials.gov) that target iRs. Most of them 
are using CTLA-4 and PD1/PD-L1 specific antibodies. But other 
similar approaches are on their way: antibodies against killer 
cell immunoglobulin-like receptors (KIR) and LAG3 are in early 
phase clinical studies of novel cancer therapies (NCT01968109, 
clinicaltrials.gov), and further reagents specific for e.g. TIM3 and 
BTLA are in preclinical development (114, 115).
iRs and iR Ligands as Biomarkers
Biomarkers that may correlate with  
disease outcome
Major research efforts are made with the aim to identify biomark-
ers that may help evaluating patient’s prognosis. For many years, 
tumor immunity parameters were rarely considered as biomarkers 
for patients with solid tumors. Rather, research focused on other 
factors related to hormonal or metabolic mechanisms. Even in 
melanoma, a disease that is since long considered as “immuno-
genic”, tumor immunity candidate biomarkers played a minor role 
(116). Now, this has changed, thanks to the new awareness of the 
importance of immunological mechanisms. Many studies focus 
on immune cells and their functions. Tumor infiltrating CD8 T 
cells are of prime interest, because they are frequently associated 
with better prognosis in the majority of human cancers (117). 
Currently, there are large multicenter efforts ongoing to determine 
whether tumor infiltration by activated CD8 T cells can be reliably 
assessed by standardized methods, and systematically evaluated 
for eventual routine staging of patients with colorectal cancers 
(118). The implementation of routine application represents a 
major challenge. In fact, the vast majority of candidate biomarkers 
never become routine tools.
During recent years, large efforts have been taken to charac-
terize inhibitory immune receptors and their ligands in cancer 
patients. Analysis of their expression in the TME revealed highly 
interesting results [reviewed in Ref. (119, 120)], with much 
attention having been paid to PD1. In renal cell carcinoma (121, 
122), follicular lymphoma (123), and soft tissue sarcomas (124) 
enhanced expression of PD1 by tumor infiltrating lymphocytes 
(TILs) was found to be associated with advanced tumor stages 
and reduced overall survival. Other studies, however, reported 
that PD1 expression was not associated with clinical outcome 
[e.g., in melanoma (125)], or correlated with a favorable outcome 
[e.g., in HPV-associated head and neck cancer patients (126)]. 
Yet, bad prognostic PD1 expression in one renal cell carcinoma 
study was linked to Foxp3 and Tregs in TIL (122), showing it 
is important to concomitantly determine which cell type (and 
T cell subset) expresses a given iR. Many studies also analyzed 
the expression of PD1 ligand 1 (PD-L1). Similar to PD1, the 
results are discrepant. In patients with mismatch-repair-proficient 
colon cancers, intratumoral expression of PD-L1 was associated 
with good prognosis (127). A similar finding was made for 
melanoma (128). In fact, intratumoral PD-L1 expression has been 
co-localized to infiltrating activated CD8 T cells (129), showing 
that presence of iR ligands may also reflect ongoing immune 
responses. However, Massi et  al. (130) found that melanoma 
patients with high-intratumoral levels of PD-L1 expression have 
a significantly shorter overall survival. Several studies simultane-
ously evaluated multiple biomarkers. Kim et  al. reported that 
PD1-positive lymphocytes and the expression of PD-L1 predicted 
poor clinical outcome of patients with soft tissue sarcoma (124). 
For LAG3, its enhanced expression was found to be associated 
with poor prognosis of patients with colorectal cancers (131). A 
similar association was found for patients with chronic lympho-
cytic leukemia (132). In the case of TIM3, associations with poor 
June 2015 | Volume 6 | Article 3109
Fuertes Marraco et al. iRs reflect more than “exhaustion”
Frontiers in Immunology | www.frontiersin.org
prognosis were found for patients with prostate cancer (133), 
renal cancer (134), gastric cancer (135), and cervical cancer (136). 
By contrast, TIM3 expression by tumor infiltrating T cells was 
associated with increased recurrence-free survival in patients 
with usual vulvar intraepithelial neoplasia (137).
Biomarkers that may Help Predicting  
Therapy outcome
Besides the search for associations with prognosis, many of the 
above-mentioned biomarkers were also evaluated with respect 
to therapy outcome prediction. The “predictive value” of a given 
biomarker is high when it correlates strongly with the subsequent 
response to a specific therapy. This is of particular interest for “per-
sonalized medicine”, because better predictions indicate that more 
efficient and less toxic treatments can be selected for individual 
patients or groups of highly defined patients. Biomarkers may not 
only suggest the outcome of a given treatment but can also support 
the improvement of drug toxicity management.
A major focus is on the role of PD-L1 expression in patients 
receiving anti-PD1 or anti-PD-L1 antibodies. Several studies 
reported that clinical responses to PD1-pathway blockade are more 
likely when tumor cells and/or immune cells express PD-L1 at 
baseline (138, 139). However, clinical responses to these therapies 
can also occur in patients where PD-L1 expression is absent or only 
very low at baseline (140), indicating that they should also have a 
chance to benefit from PD1-pathway blockade. In fact, currently, 
there is no biomarker that can be used for patient selection for 
treatments with antibodies for iRs (140).
Simultaneous assessment of multiple biomarkers may also 
be useful for predicting therapy outcome. In melanoma samples 
before treatment with the PD1 specific antibody pembrolizumab, 
several immune features were associated with subsequent clinical 
responses, i.e. enrichments of CD8-, PD1-, and PD-L1-expressing 
cells inside tumors and at invasive margins, with close proximity 
of PD1/PD-L1, and increased TCR diversity (141).
In humans, the possibilities for assessing functional roles are 
limited. Nevertheless, cellular assays allow determining functional 
roles at the level of individual cells, or groups of highly defined 
cells. Gros et al. found that tumor-reactive T cells in  situ show 
increased PD1 expression, more so than expression of TIM3, 
LAG3, or CD137 (142). Fourcade et  al. demonstrated that the 
combined expression of PD1 and TIM3 identified T cells with 
diminished functional capabilities (143). However, functional 
studies in absence of the cells’ natural environment (i.e. outside 
of the organisms) may give misleading results. As outlined above, 
T cells that express certain iRs may show reduced function because 
the receptor indeed mediates inhibition, or because the iR-positive 
cells are in a different functional state, with different activation 
and/or differentiation (72).
Triggering of expression of many immune genes is promoted 
by IFNγ, which is produced by activated immune cells in tumors. 
PD-L1 is a typical example, and may be taken as a “marker” 
for immune activation and ongoing CTL activity in  situ (129). 
However, PD-L1 can also be constitutively expressed by tumor 
cells, such as found in a minority of melanoma patients. The com-
bined assessment of PD-L1 expression and CD8 T cells in tumors 
is currently being used to distinguish scenarios of constitutive 
versus induced PD-L1 expression, whereby the quantification of 
CD8 T cells serves as parameter of immune cell activation in situ 
(142, 144).
Overall, it remains difficult to draw conclusions from human 
studies. iR expression in the TME can be a good sign when 
 anti-tumor immune responses are nevertheless taking place and 
thus contribute to favorable clinical outcomes. As mentioned, iR 
expression is frequently up-regulated by T cell activation and may be 
thus a sign of ongoing immune responses. In turn, iR expression may 
be associated with unfavorable clinical course when occurring in 
(relative) absence of anti-tumor T cell responses, for example, when 
tumors constitutively express immune inhibitory molecules (e.g. 
PD-L1) and fundamentally avoid and or block (almost) any effective 
immune response against the cancer, even under immunotherapy.
Recommendations for immune Monitoring 
of T cell Function
Biological readouts do often not allow conclusions for individual 
patients. It remains challenging to identify biomarkers, as most of 
them end up not being useful for routine clinical management of 
individual patients. Nevertheless, biomarkers research is often very 
worthwhile, through their contributions for identifying disease 
mechanisms.
When analyzing immune responses from patients, caution is 
required for the interpretation of results. In view of the increasing 
clinical importance of iRs, patient parameters are now frequently 
quantified by various methods such as flow cytometry or molecular 
techniques. From the literature as reviewed here, it becomes clear 
that the quantification of iR expression by T cells does not allow 
to conclude that they have impaired functions. Besides consider-
ing exhaustion and the TME, it is crucial and possible to analyze 
parameters of T cell differentiation and activation. Subsets at dif-
ferent stages of differentiation can be distinguished by analyzing T 
cells with regard to lymph node homing receptors (such as CCR7 
and CD62L), and differentiation markers (e.g. KLRG-1 and CD45 
isotypes). The separate analysis of naïve cells is most important, 
but memory cells should also be distinguished from effector cells, 
as they may also differ largely for iR expression and functions. 
As mentioned in the previous sections, shifts in iR expression of 
total cells are often due to changes in differentiation, rather than 
changes of iR expression within a particular differentiation subset. 
Similarly, changes in T cell activation are associated with altered iR 
expression. Therefore, activation markers should also be included, 
to evaluate this possibility as driver for iR expression.
Regarding the analyses of functional properties, the question 
remains open whether the available in vitro methods allow con-
cluding on in vivo T cell functions. The high degree of context 
dependency and the fact that multiple receptors may simultane-
ously be involved in controlling T cell function in vivo should be 
taken into account. In vitro assays often fail to reproduce the reality. 
Great care should be taken for drawing conclusions. Nevertheless, 
Key concePT 5 | Favorable clinical outcomes
The expression of multiple iRs can reflect recent or ongoing T cell activation – 
iRs may, in fact, mark the cells that responded to a given stimulus (including 
therapy) and be good prognostic indicators.
June 2015 | Volume 6 | Article 31010
Fuertes Marraco et al. iRs reflect more than “exhaustion”
Frontiers in Immunology | www.frontiersin.org
in conjunction with results from increasingly sophisticated and 
realistic mouse models, it is worthwhile to perform functional 
in vitro experiments with human cells, particularly also for the 
identification of synergistic or antagonistic effects between dif-
ferent iRs and activatory receptors, for example, 4-1BB. It may be 
useful to characterize the co-expression of multiple iRs, together 
with other receptors. The recent discovery that TIM3 mediates 
different functions depending on co-expression of CEACAM-1 
(67) represents a typical example for the need to identify possible 
receptor pairing with functional relevance.
It is necessary to elucidate the contradictory results obtained 
from studies analyzing iRs and their ligands, and their associations 
with favorable or unfavorable clinical outcome. Distinguishing 
tumors in presence versus absence of anti-tumor T cells may 
lead to a better understanding. Possibly, up-regulation of iRs 
and iR ligands in the TME in presence of anti-cancer T cells may 
be favorable indicators because they reflect ongoing anti-cancer 
immune responses. By contrast, in absence of immune responses, 
the expression of iRs and iR ligands point to a constitutive immune 
blockade, which is often associated with unfavorable prognosis 
and non-responsiveness to immunotherapy.
For the future, advances in basic science are necessary for 
improved understanding and interpretation of clinical data. For 
the time being, detailed characterization of T cell activation and 
differentiation represents already a significant step forward toward 
a comprehensive characterization and interpretation of iR expres-
sion, providing insight in patient’s immune status.
concluding Remarks
The success of “checkpoint blockade” therapies in clinical oncology 
is probably the best proof that iRs can play crucial roles in the regu-
lation of cellular immune responses. However, the mechanisms 
of action of these novel therapies are still poorly understood, and 
probably involve multiple cell types and functions. iRs do not only 
inhibit the effector T cells that express them but can also act early in 
the generation of an immune response, and/or promote inhibitory 
functions of immune suppressive cell types such as Treg cells or 
myeloid cells. Importantly, the sole expression of iRs does not allow 
to directly conclude on the functional status of T cells. Historically, 
iR expression was associated with T cell “exhaustion,” i.e. those 
T cells with reduced effector functions found in chronic infec-
tion and in the TME. iRs were considered “guilty by association”, 
without systematic critical evaluation of their functional impact. 
Importantly, iRs are also frequently expressed by highly functional 
T cells such as the ones that predominate in acute infections. This is 
explained by the fact that T cell activation and T cell differentiation 
lead to strong upregulation of many iRs, as part of the physiological 
balance of T cell activation, even though these cells remain highly 
functional. Clearly, the impact of iRs on T cell function is context-
dependent, as the result of the sum of activatory and inhibitory 
signals. For research and the immune monitoring of patients, it is 
important to primarily study immune cell functions in vivo, and to 
carefully consider T cell activation and differentiation by subset 
analyses for the interpretation of iR expression data.
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